# Antidote Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/antidote-technologies

- Industry: Healthcare
- Headquarters: London, UK
- Website: www.antidote.me
- Total disclosed funding: $17M
- Latest round: Series B (Feb 5, 2015)
- Investors on record: 3

## About

Based in London, UK, and founded in 2010 by Eithan Ephrati, Jessica Mann, and Pablo Graiver, Antidote Technologies, Inc., a.k.a. Antidote operates as a health-tech company that uses precision recruitment to match the right patients with the right trials through the integration of data-driven technologies, domain experience, digital expertise, diverse partner network, and personalized patient and site services. In June 2021, Antidote Technologies, Inc. raised USD 23.2 million in venture funding led by LBO France, with participation from Merck Global Health Innovation Fund, Octopus Ventures, and Smedvig Capital. As of June 2021, Laurent Schockmel is the CEO of the company.

Antidote's primary product is a platform that facilitates the vital connections between patients and clinical trials. The company uses precision recruitment to match the right patients with the right trials to strike the right balance between technology and human touch to deliver patient engagement. This solution serves as a crucial link, enabling patients to access and participate in clinical research that can have an impact on their lives. By addressing the challenge of patient recruitment, Antidote is streamlining the process and accelerating medical advancements.

## Funding rounds

- Series B, Feb 5, 2015, $14M — Amadeus Capital Partners, Smedvig Capital, Octopus Investments
- Series A, Apr 30, 2013, $3.1M — Amadeus Capital Partners, Octopus Investments

## Investors

- Amadeus Capital Partners (https://capitalatlas.ai/funds/amadeus-capital-partners) — Series A, Series B
- Octopus Investments (https://capitalatlas.ai/funds/octopus-investments) — Series A, Series B
- Smedvig Capital (https://capitalatlas.ai/funds/smedvig-capital) — Series B